Your shopping cart is currently empty

SCO-267 is a full agonist of GPR40/FFAR1 with an EC50 of 12 nM, effectively stimulating insulin secretion and GLP-1 release in diabetic rats, improving glucose tolerance, and can be used for the treatment of type 2 diabetes.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $139 | - | In Stock | |
| 5 mg | $359 | - | In Stock | |
| 10 mg | $587 | - | In Stock | |
| 25 mg | $1,170 | - | In Stock | |
| 50 mg | $1,890 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $486 | - | In Stock |
| Description | SCO-267 is a full agonist of GPR40/FFAR1 with an EC50 of 12 nM, effectively stimulating insulin secretion and GLP-1 release in diabetic rats, improving glucose tolerance, and can be used for the treatment of type 2 diabetes. |
| In vitro | Method: The activation of G protein-coupled receptor signaling pathways by SCO-267 was evaluated in CHO cells, including Gαq, Gαs, Gα12/13 pathways and β-arrestin recruitment. Its allosteric interaction with fasiglifam and an endogenous ligand was also analyzed.[1] Result: SCO-267 activated the Gαq, Gαs, and Gα12/13 pathways and induced β-arrestin recruitment. It exhibited allosteric modulation with fasiglifam and an endogenous ligand.[1] |
| In vivo | Method: In the N-STZ rat model, SCO-267 was administered orally at doses of 1 or 10 mg/kg to evaluate its effects on insulin sensitivity and blood glucose levels. Result: SCO-267 improved insulin sensitivity and exerted a sustained glucose-lowering effect. [1] |
| Synonyms | SCO267 |
| Molecular Weight | 614.77 |
| Formula | C36H46N4O5 |
| Cas No. | 1656261-09-4 |
| Smiles | C(N(CC(C)(C)C)C=1N=C(C)C=CC1)(=O)C2=C(C=C(OC)C=C2)N3CCC(COC4=CC([C@@H](CC(O)=O)[C@@H]5CC5)=CC=N4)CC3 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (130.13 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (5.37 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.